Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Better Growth Stock: Axsome vs. CRISPR Therapeutics
05:30am, Sunday, 16'th Apr 2023
Axsome last year launched two products that could bring in revenue of more than $1 billion each. CRISPR Therapeutics recently completed regulatory requests for its first potential product.
Is CRISPR Therapeutics Stock a Buy Now?
10:23am, Friday, 14'th Apr 2023
CRISPR Therapeutics' exa-cel is racing towards approval in the U.S. and Europe. The market opportunity for this gene-editing therapy could be massive.
CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?
04:36am, Friday, 14'th Apr 2023
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
Crispr Therapeutics stock jumps following analyst upgrade from Cantor Fitzgerald
04:54pm, Thursday, 13'th Apr 2023
Yahoo Finance Live discusses a rise in Crispr Therapeutics stock after Cantor Fitzgerald upgraded the company to an 'Overweight' rating.
3 Stocks Making Outsized Moves Today
02:59pm, Thursday, 13'th Apr 2023
Stocks are bouncing in the wake of the latest encouraging inflation reading.
Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock
02:46pm, Thursday, 13'th Apr 2023
Shares of Crispr Therapeutics (NASDAQ: CRSP ) stock are up by about 15% today following continued purchases by Cathie Wood's ARK Invest and an initiation of coverage from Cantor Fitzgerald's Olivia Br
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
02:25pm, Thursday, 13'th Apr 2023
Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for
Why Shares of CRISPR Therapeutics Jumped Thursday
11:58am, Thursday, 13'th Apr 2023
CRISPR and Vertex Pharmaceuticals are jointly developing a gene-editing therapy to treat sickle cell disease and tranfusion-dependent beta thalassemia. The therapy is in Phase 3 trials and the compani
2 Nasdaq Growth Stocks That Are Screaming Buys in April
10:15am, Thursday, 13'th Apr 2023
Vertex Pharmaceuticals has a relatively safe top line, and more growth on the way. CRISPR Therapeutics is on track to start realizing revenue growth like wild.
These Up-and-Coming Stocks Are Screaming Buys Right Now
05:30am, Thursday, 13'th Apr 2023
Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorder candidate with blockbuster potential.
Could This Move Make Vertex's Next Blockbuster Even Bigger?
05:30am, Wednesday, 12'th Apr 2023
Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.
Where Will CRISPR Therapeutics Be in 5 Years?
07:45am, Sunday, 09'th Apr 2023
CRISPR's business needs consistent revenue that could come from its gene-editing therapy exa-cel. Investors shouldn't expect profitability anytime soon, however, as the company's losses are deep and i
CRISPR Stock: Bull vs. Bear
05:30am, Saturday, 08'th Apr 2023
CRISPR shares have declined quite a bit from a high a few years ago. But potential good news may be baked into the current price.
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
01:14pm, Friday, 07'th Apr 2023
Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
01:42pm, Thursday, 06'th Apr 2023
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
